Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) TNFRSF10B Antibodies:
anti-Human TNFRSF10B Antibodies:
anti-Mouse (Murine) TNFRSF10B Antibodies:
Go to our pre-filtered search.
Human Polyclonal TNFRSF10B Primary Antibody for FACS, ICC - ABIN4361766
Basile, Zacny, Münger et al.: The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the ... in The Journal of biological chemistry 2001
Show all 37 Pubmed References
Human Polyclonal TNFRSF10B Primary Antibody for FACS, ICC - ABIN4361767
Cuello, Ettenberg, Clark, Keane, Posner, Nau, Dennis, Lipkowitz et al.: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that ... in Cancer research 2001
Show all 18 Pubmed References
Human Monoclonal TNFRSF10B Primary Antibody for CyTOF, FACS - ABIN4900599
Barbarotto, Corallini, Rimondi, Fadda, Mischiati, Grill, Vaccarezza, Celeghini: Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. in Journal of cellular biochemistry 2008
Show all 14 Pubmed References
Human Monoclonal TNFRSF10B Primary Antibody for FACS - ABIN4898055
Peppa, Gill, Reynolds, Easom, Pallett, Schurich, Micco, Nebbia, Singh, Adams, Kennedy, Maini: Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. in The Journal of experimental medicine 2013
Show all 13 Pubmed References
Human Monoclonal TNFRSF10B Primary Antibody for FACS - ABIN4898056
Gupta, Francis, Nair, Mo, Aggarwal et al.: Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 ... in The Journal of biological chemistry 2013
Show all 13 Pubmed References
Human Monoclonal TNFRSF10B Primary Antibody for FACS, Func - ABIN1169245
Sprick, Rieser, Stahl, Grosse-Wilde, Weigand, Walczak: Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. in The EMBO journal 2002
Show all 6 Pubmed References
Human Monoclonal TNFRSF10B Primary Antibody for - ABIN1383912
Sato, Niessner, Kopecky, Frye, Goronzy, Weyand: TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. in The Journal of experimental medicine 2006
Show all 3 Pubmed References
Mouse (Murine) Polyclonal TNFRSF10B Primary Antibody for CyTOF, FACS - ABIN4900408
Park, Wu, Choi, Najafi, Emami, Safa: P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. in Biochemical pharmacology 2006
Show all 3 Pubmed References
Human Polyclonal TNFRSF10B Primary Antibody for IHC (p), WB - ABIN3044205
Liu, Zuo, Wang, Chen, Yang, Wang, Zhu: miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. in Oncotarget 2014
Show all 2 Pubmed References
Human Monoclonal TNFRSF10B Primary Antibody for IP - ABIN1383915
Vermot-Desroches, Sergent, Bonnin, Wijdenes: Characterization of monoclonal antibodies directed against trail or trail receptors. in Cellular immunology 2005
Show all 2 Pubmed References
Results show that downregulation of DR4 (show HLADRB4 Antibodies) and DR5 by SLC26A2 (show SLC26A2 Antibodies) confers resistance to TRAIL.
Study provides direct biophysical evidence that Death Receptor 5 disulfide-linked transmembrane (TM)-dimers open in response to ligand binding. Then, to probe the importance of the closed-to-open TM domain transition in the overall energetics of receptor activation, point-mutants (alanine to phenylalanine) in the predicted, tightly packed TM domain dimer interface were designed and tested.
High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer cells and xenograft tumors.
Oridonin analog CYD (show CYBB Antibodies)-6-28 induces apoptosis at least partially by inducing the expression of death receptor 5 in breast neoplasms.
The authors show that cholesterol is necessary for the covalent dimerization of DR5 transmembrane domains.
Mono treatment with lexatumumab was not sufficient to induce apoptosis in pancreatic cancer cells, whereas focal adhesion kinase inhibitor PF573228 significantly sensitized lexatumumab-induced apoptosis. Western blotting analysis revealed that lexatumumab and PF573228 combination treatment increased death receptor 5 but decreased Bcl-xL (show BCL2L1 Antibodies) expression.
We demonstrate that PBOX-15 can enhance TRAIL-induced apoptosis by upregulation of DR5, reduction of cellular mitochondrial potential, activation of the caspase (show CASP3 Antibodies) cascade and downregulation of PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies), c-FLIP (show CFLAR Antibodies), Mcl-1 (show MCL1 Antibodies) and IAP (show ALPI Antibodies) survival pathways
The nanovectorization of TRAIL enhanced its binding to both DR4 (show HLADRB4 Antibodies) and DR5 receptors at 37 degrees C and could potentially sensitized cancer cells to TRAIL induced apoptosis through simultaneous activation of DR4 (show HLADRB4 Antibodies) and DR5 as described in this paper for the non-small lung carcinoma cell line (H1703), the two hepatocarcinoma cell lines (SK-Hep1, HUH) and the colon carcinoma cell line (HCT116WT).
we found that CQ decreased the expression of Cbl (show CBL Antibodies), an E3 ligase of DR5, and knock-down of Cbl (show CBL Antibodies) markedly enhanced DR5 up-regulation. Other lysosomal inhibitors, including monensin and nigericin, also up-regulated DR5 and sensitized TRAIL-mediated apoptosis
MG132 possesses anti-gallbladder cancer potential that correlate with regulation of DR5-dependent pathway.
Authors demonstrate, for the first time, expression of TNF-related apoptosis-inducing ligand (TRAIL (show TNFSF10 Antibodies)) and its signaling death receptor 5 (DR5) in the murine inner ear.
Malignant transformation in the endometrium is related to reduction of membrane DR4 (show HLADRB4 Antibodies) and DR5 expression.
TRAIL expression by osteoclast-like cells is increased in the presence of RANKL (show TNFSF11 Antibodies) and after scraping; DcR2 (show TNFRSF10D Antibodies) expression peaks at 24 hours, and and decreases at 5 days; DR5 expression peaks at 5 days
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34 (show CD34 Antibodies)(+) cells.
TRAIL-DR5 interaction promoted malignant behaviors of B16F10 cells.
results suggest that the transmembrane domains together with their adjacent stalk regions can play a major role in control of death receptor activation thereby contributing to cell type specific differences in TRAILR1 and TRAILR2 signaling
DR5 is selectively expressed by neuroprogenitor cells and newborn neurons.
Results suggest that excessive iodine could induce TRAIL and DR5 abnormal expression in thyroid. TRAIL band with DR5 to promote follicular cells apoptosis thus mediate thyroid destruction in EAT.
NK cells inhibit dendritic cell cross-priming, but not direct priming, in a TRAIL/DR5-dependent manner.
Antibody-based therapy targeting DR5 is an efficient strategy not only to eliminate TRAIL-sensitive tumor cells.
The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene.
tumor necrosis factor receptor superfamily, member 10b
, death receptor-M2
, death receptor-M1
, Fas-like protein
, TNF-related apoptosis-inducing ligand receptor 2
, apoptosis inducing protein TRICK2A/2B
, apoptosis inducing receptor TRAIL-R2
, cytotoxic TRAIL receptor-2
, death domain containing receptor for TRAIL/Apo-2L
, death receptor 5
, p53-regulated DNA damage-inducible cell death receptor(killer)
, tumor necrosis factor receptor superfamily member 10B
, tumor necrosis factor receptor-like protein ZTNFR9
, KILLER/DR5 TRAIL death-inducing receptor